Article thumbnail

Clonogenic ability in vitro after lexatumumab (1 µg/ml) and DTIC (50 µg/ml) treatment of the cell lines.

By Birgit Engesæter (133861), Olav Engebraaten (133864), Vivi Ann Flørenes (133867) and Gunhild Mari Mælandsmo (56780)


<p>(A) FEMX-1 and (B) HHMS. The cells were seeded in six well plates and the next day exposed to the indicated treatment. Two weeks later the colonies were fixed, stained with 0.04% crystal violet and counted. Results are expressed relative to untreated control cells and are presented as mean ± standard error of the mean (SEM) of three parallel experiments. Significant difference in clonogenicity after combination treatments relative to DTIC or lexatumumab mono-treatment is indicated by (*).</p

Topics: Cell Biology, Biotechnology, Developmental Biology, Cancer, vitro, lexatumumab, dtic
Year: 2012
DOI identifier: 10.1371/journal.pone.0045492.g003
OAI identifier:
Provided by: FigShare
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.